


Listing of Claims:

1. A compound of the Formula I:



or a pharmaceutically acceptable salt thereof, wherein:

R^1 is halo, $-S(C_1-C_4)alkyl$, $-S(C_3-C_7)cycloalkyl$, or $-S[halo(C_1-C_4)alkyl]$;

X is CH or N;

R^2 is hydrogen, halo, $(C_1-C_4)alkyl$, or $halo(C_1-C_4)alkyl$;

R^3 is halo, $(C_1-C_4)alkyl$, or $halo(C_1-C_4)alkyl$;

R^4 is $(C_3-C_7)cycloalkyl$ or 4-7 membered heterocyclyl, each of which are optionally substituted with 1 to 3 groups selected from halo, $(C_1-C_4)alkyl$, $halo(C_1-C_4)alkyl$, $(C_1-C_4)alkoxy$, $halo(C_1-C_4)alkoxy$, and $-NR^aR^b$;

R^a is hydrogen, $(C_1-C_4)alkyl$, or $halo(C_1-C_4)alkyl$;

R^b is $(C_1-C_4)alkyl$, $halo(C_1-C_4)alkyl$, or 4-7 membered heterocyclyl, wherein said heterocyclyl is optionally substituted with 1 to 3 groups selected from halo, $(C_1-C_4)alkyl$, $halo(C_1-C_4)alkyl$, $(C_1-C_4)alkoxy$, and $halo(C_1-C_4)alkoxy$; or

R^a and R^b together with the nitrogen atom to which they are attached form a 4-7 membered heterocyclyl optionally substituted with 1 to 3 groups selected from halo, $(C_1-C_4)alkyl$, $halo(C_1-C_4)alkyl$, and $-OR^c$;

R^c is $(C_1-C_4)alkyl$, $halo(C_1-C_4)alkyl$, or $(C_3-C_7)cycloalkyl$; and

R^5 is halo, $(C_1-C_4)alkyl$, or $halo(C_1-C_4)alkyl$.

2. The compound of Claim 1, wherein:

R^1 is halo or $-S(C_1-C_4)alkyl$;

R^2 is halo;

R^3 is $(C_1-C_4)alkyl$;

R^4 is $(C_3-C_7)cycloalkyl$ or $(C_4-C_7)heterocyclyl$, each of which are optionally substituted with 1 to 2 groups selected from $halo(C_1-C_4)alkyl$ and $-NR^aR^b$;

R^a is hydrogen or $(C_1-C_4)alkyl$;


R^b is $(C_1-C_4)alkyl$ or $(C_4-C_7)heterocyclyl$, wherein said heterocyclyl is optionally substituted with $halo(C_1-C_4)alkyl$; or

R^a and R^b together with the nitrogen atom to which they are attached form a 4-7 membered nitrogen containing heterocyclyl optionally substituted with 1 to 3 groups selected from halo and $-OR^c$;

R^c is (C_1-C_4) alkyl, halo (C_1-C_4) alkyl, or (C_3-C_7) cycloalkyl; and

R^5 is halo or (C_1-C_4) alkyl.

3. The compound of Claims 1 or 2, wherein the compound is of the Formula **II**:




or a pharmaceutically acceptable salt thereof.

4. The compound of any one of Claims 1 to 3, wherein R^1 is chloro.

5. The compound of any one of Claims 1 to 4, wherein R^1 is $-SCH_3$.


6. The compound of any one of Claims 1 to 5, wherein R^4 is cyclohexyl or piperidinyl, each of which are optionally substituted with 1 to 2 groups selected from halo (C_1-C_4) alkyl and $-NR^aR^b$.

7. The compound of any one of Claims 1 to 6, wherein the compound is of the Formula **III**:




or a pharmaceutically acceptable salt thereof, wherein R^6 is halo (C_1-C_4) alkyl.

8. The compound of any one of Claims 1 to 7, wherein the compound is of the Formula **IV**:





or a pharmaceutically acceptable salt thereof.

9. The compound of any one of Claims 1 to 6, wherein the compound is of the Formula **(V)**:




or a pharmaceutically acceptable salt thereof.

10. The compound of any one of Claims 1 to 6 and 9, wherein the compound is of the Formula:



or a pharmaceutically acceptable salt thereof.

11. The compound of any one of Claims 1 to 6, 9, and 10, wherein the compound is of the Formula:




or a pharmaceutically acceptable salt thereof.


12. The compound of any one of Claims 1 to 6 and 9 to 11, wherein R^b is (C_1-C_4) alkyl or oxetanyl, wherein said oxetanyl is optionally substituted with halo (C_1-C_4) alkyl; or R^a and R^b together with the nitrogen atom to which they are attached form an azetidiny optionally substituted with halo or $-OR^c$.

13. The compound of any one of Claims 1 to 6 and 9 to 12, wherein R^a is hydrogen or methyl; and R^b is methyl or oxatanyl, wherein said oxetanyl is optionally substituted with $-CH_2F$ or $-CF_3$.


14. The compound of any one of Claims 1 to 6 and 9 to 13, wherein R^a and R^b together with the nitrogen atom to which they are attached form an azetidiny optionally substituted with 1 to 2 fluoro or $-OR^c$; and R^c is $-CH_3$, $-CHF_2$, or cyclopropyl.

15. The compound of Claim 1, wherein the compound is of the Formula:







;




;









;




;




;






; or



;


or a pharmaceutically acceptable salt thereof.

16. The compound of any one of Claims 1 to 6, and 9 to 15, wherein the group



and NR^aR^b are oriented trans about the cyclohexyl.

17. The compound of any one of Claims 1 to 6, and 9 to 15, wherein the group




and NR^aR^b are oriented cis about the cyclohexyl.


18. The compound of any one of Claims 1 to 17, wherein the stereochemical configuration of the chiral center of the 1,3-dioxolanyl is R.

19. The compound of any one of Claims 1 to 17, wherein the stereochemical configuration of the chiral center of the 1,3-dioxolanyl is S.


20. The compound of Claim 1, wherein the compound is of the Formula:



;



; or



;

or a pharmaceutically acceptable salt thereof.


21. A pharmaceutical composition comprising the compound of any one of Claims 1 to 20, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

22. A method for treating cancer in a subject, comprising administering to the subject an effective amount of a compound according to any one of Claims 1 to 20, or a pharmaceutically acceptable salt thereof, or the composition of Claim 21.

23. The method of Claim 22, wherein the cancer is selected from breast cancer, prostate cancer, colon cancer, renal cell carcinoma, glioblastoma multiforme cancer, bladder cancer, melanoma, bronchial cancer, lymphoma, cholangiosarcoma, multiple myeloma, lung cancer, ovarian cancer, and liver cancer.

Listing of Claims:

1. A compound of the Formula I:



or a pharmaceutically acceptable salt thereof, wherein:

R¹ is halo or -S(C₁-C₄)alkyl;

X is CH or N;

R² is hydrogen, halo, (C₁-C₄)alkyl, or halo(C₁-C₄)alkyl;

R³ is halo, (C₁-C₄)alkyl, or halo(C₁-C₄)alkyl;

R⁴ is (C₃-C₇)cycloalkyl or 4-7 membered heterocyclyl, each of which are optionally substituted with 1 to 3 groups selected from halo, (C₁-C₄)alkyl, halo(C₁-C₄)alkyl, (C₁-C₄)alkoxy, halo(C₁-C₄)alkoxy, and -NR^aR^b;

R^a is hydrogen, (C₁-C₄)alkyl, or halo(C₁-C₄)alkyl;

R^b is (C₁-C₄)alkyl, halo(C₁-C₄)alkyl, or 4-7 membered heterocyclyl, wherein said heterocyclyl is optionally substituted with 1 to 3 groups selected from halo, (C₁-C₄)alkyl, halo(C₁-C₄)alkyl, (C₁-C₄)alkoxy, and halo(C₁-C₄)alkoxy; or

R^a and R^b together with the nitrogen atom to which they are attached form a 4-7 membered heterocyclyl optionally substituted with 1 to 3 groups selected from halo, (C₁-C₄)alkyl, halo(C₁-C₄)alkyl, and -OR^c;

R^c is (C₁-C₄)alkyl, halo(C₁-C₄)alkyl, or (C₃-C₇)cycloalkyl; and

R⁵ is halo, (C₁-C₄)alkyl, or halo(C₁-C₄)alkyl.

2. The compound of Claim 1, wherein:

R² is halo;

R³ is (C₁-C₄)alkyl;

R⁴ is (C₃-C₇)cycloalkyl or (C₄-C₇)heterocyclyl, each of which are optionally substituted with 1 to 2 groups selected from halo(C₁-C₄)alkyl and -NR^aR^b;

R^a is hydrogen or (C₁-C₄)alkyl;


R^b is (C₁-C₄)alkyl or (C₄-C₇)heterocyclyl, wherein said heterocyclyl is optionally substituted with halo(C₁-C₄)alkyl; or

R^a and R^b together with the nitrogen atom to which they are attached form a 4-7 membered nitrogen containing heterocyclyl optionally substituted with 1 to 3 groups selected from halo and -OR^c;

R^c is (C₁-C₄)alkyl, halo(C₁-C₄)alkyl, or (C₃-C₇)cycloalkyl; and

R⁵ is halo or (C₁-C₄)alkyl.

3. The compound of Claims 1 or 2, wherein the compound is of the Formula II:




or a pharmaceutically acceptable salt thereof.

4. The compound of any one of Claims 1 to 3, wherein R¹ is chloro.

5. The compound of any one of Claims 1 to 4, wherein R¹ is -SCH₃.


6. The compound of any one of Claims 1 to 5, wherein R⁴ is cyclohexyl or piperidinyl, each of which are optionally substituted with 1 to 2 groups selected from halo(C₁-C₄)alkyl and -NR^aR^b.

7. The compound of any one of Claims 1 to 6, wherein the compound is of the Formula III:




or a pharmaceutically acceptable salt thereof, wherein R⁶ is halo(C₁-C₄)alkyl.

8. The compound of any one of Claims 1 to 7, wherein the compound is of the Formula
IV:





or a pharmaceutically acceptable salt thereof.

9. The compound of any one of Claims 1 to 6, wherein the compound is of the Formula
(V):




or a pharmaceutically acceptable salt thereof.

10. The compound of any one of Claims 1 to 6 and 9, wherein the compound is of the
Formula:



or a pharmaceutically acceptable salt thereof.

11. The compound of any one of Claims 1 to 6, 9, and 10, wherein the compound is of the Formula:




or a pharmaceutically acceptable salt thereof.






12. The compound of any one of Claims 1 to 6 and 9 to 11, wherein R^b is (C₁-C₄)alkyl or oxetanyl, wherein said oxetanyl is optionally substituted with halo(C₁-C₄)alkyl; or R^a and R^b together with the nitrogen atom to which they are attached form an azetidinyl optionally substituted with halo or -OR^c.







13. The compound of any one of Claims 1 to 6 and 9 to 12, wherein R^a is hydrogen or methyl; and R^b is methyl or oxatanyl, wherein said oxetanyl is optionally substituted with -CH₂F or -CF₃.



14. The compound of any one of Claims 1 to 6 and 9 to 13, wherein R^a and R^b together with the nitrogen atom to which they are attached form an azetidinyl optionally substituted with 1 to 2 fluoro or -OR^c; and R^c is -CH₃, -CHF₂, or cyclopropyl.

15. The compound of Claim 1, wherein the compound is of the Formula:











or a pharmaceutically acceptable salt thereof.

16. The compound of any one of Claims 1 to 6, and 9 to 15, wherein the group






17. The compound of any one of Claims 1 to 6, and 9 to 15, wherein the group



18. The compound of any one of Claims 1 to 17, wherein the stereochemical configuration of the chiral center of the 1,3-dioxolanyl is R.


19. The compound of any one of Claims 1 to 17, wherein the stereochemical configuration of the chiral center of the 1,3-dioxolanyl is S.

20. The compound of Claim 1, wherein the compound is of the Formula:




or a pharmaceutically acceptable salt thereof.

21. The compound of Claim 1, wherein the compound is of the Formula:



or a pharmaceutically acceptable salt thereof.

22. The compound of Claim 1, wherein the compound is of the Formula:



or a pharmaceutically acceptable salt thereof.

23. A pharmaceutical composition comprising the compound of any one of Claims 1 to 22, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

24. Use of the compound of any one of Claims 1 to 22, or the composition of Claim 23, in the manufacture of a medicament for the treatment of a cancer responsive to the modulation of EZH2.

25. The use of Claim 24, wherein the cancer is selected from breast cancer, prostate cancer, colon cancer, renal cell carcinoma, glioblastoma multiforme cancer, bladder cancer, melanoma, bronchial cancer, lymphoma, cholangiosarcoma, multiple myeloma, lung cancer, ovarian cancer, and liver cancer.